It is my honor and pleasure to bring probably one of the most, as I've said, one of the most

decorated doc as we've had in the high wire to date.

Dr. Roger Hodgkinson, look at that CV.

It's amazing.

He's had fellow ships.

He's been chairman of journals.

I mean, he's worked in so many important places.

And so we're honored right now to be joined by somebody that actually can speak to this.

I don't know if you got a chance to see that interview, Dr. Hodgkinson.

But this myocarditis, swelling of the heart, we keep hearing, well, it's mild in most cases.

That didn't sound mild to me.

That sounds life changing for a med.

How many people is this going to be life changing for?

We don't know.

And that's the problem.

The big point about clinical trials is you don't know what you don't know.

It's exactly why we do it.

Myocarditis, as the CDC described it, quote, mild, quote, unbalanced, close quotes.

Myocarditis is never mild, particularly in young, healthy males.

It's an inflammation of the heart muscle, the pump of the body.

And we don't know what percentage of the heart muscles will have died in any one attempt attack of myocarditis.

The big thing about heart muscles is heart muscle fibers.

...